Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,280 Mln
Revenue (TTM)
$317 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.8
Industry P/E
--
EV/EBITDA
-8.3
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
22,203,300
CFO
$-1,147.99 Mln
EBITDA
$-1,462.51 Mln
Net Profit
$-1,429.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| -5.4 | -9.5 | -13.5 | 38.3 | 64.4 | 21.5 | 13.9 |
|
BSE Sensex*
| 5.2 | 7.2 | 8.4 | 12.8 | 15.9 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| 33.0 | -20.3 | 242.5 | -23.8 | 22.0 | -19.2 | 22.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
|
291.8 | 6,280.4 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 8.8 |
| 99.5 | 6,297.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.4 | |
| 56.2 | 10,350.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.5 | 5,161.2 | 774.0 | -416.6 | -53.5 | -- | -- | 55.7 | |
| 49.0 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 296.4 | 8,384.8 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.3 | 14.1 | |
| 23.7 | 9,289.5 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.3 | 11,755.2 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.3 | 4.6 | |
| 71.0 | 5,099.9 | 0.0 | -300.9 | -- | -28.2 | -- | 5.1 | |
| 35.3 | 3,512.4 | 2,233.4 | -248.4 | 9.6 | -21 | -- | 3.1 |
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor... beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428 Read more
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
Headquarters
West Conshohocken, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Madrigal Pharmaceuticals Inc (MDGL) stood at $ 1,164 Mln as on 31-Mar-25
The share price of Madrigal Pharmaceuticals Inc (MDGL) is $291.82 (NASDAQ) as of 15-May-2025 16:00 EDT. Madrigal Pharmaceuticals Inc (MDGL) has given a return of 64.36% in the last 3 years.
Madrigal Pharmaceuticals Inc (MDGL) has a market capitalisation of $ 6,280 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Madrigal Pharmaceuticals Inc (MDGL) is 8.84 times as on 15-May-2025, a 296% premium to its peers’ median range of 2.23 times.
Since, TTM earnings of Madrigal Pharmaceuticals Inc (MDGL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Madrigal Pharmaceuticals Inc (MDGL) and enter the required number of quantities and click on buy to purchase the shares of Madrigal Pharmaceuticals Inc (MDGL).
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Address: Four Tower Bridge, West Conshohocken, PA, United States, 19428
The CEO & director of Dr. Rebecca A. Taub M.D.. is Madrigal Pharmaceuticals Inc (MDGL), and CFO & Sr. VP is Dr. Rebecca A. Taub M.D..
There is no promoter pledging in Madrigal Pharmaceuticals Inc (MDGL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
|
|
864
|
|
|
756
|
|
|
658
|
|
|
626
|
|
|
546
|
|
|
542
|
| Madrigal Pharmaceuticals Inc. (MDGL) | Ratios |
|---|---|
|
Return on equity(%)
|
-52.64
|
|
Operating margin(%)
|
-118.93
|
|
Net Margin(%)
|
-123.38
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Madrigal Pharmaceuticals Inc (MDGL) was $0 Mln.
$8.96
(
